Type 1 diabetes

Concern over biosimilar insulin substitution

A proposed move to allow pharmacists to substitute cheaper biosimilar insulins for originator brands could harm patients, Diabetes Australia has warned. In a submission to the National Health Amendment (Pharmaceutical Benefits) Bill 2015 the organisation said it was strongly opposed to “a flagging” of pharmacy level substitution of any biosimilar insulin product. Unlike generics, biosimilars were different ...

Already a member?

Login to keep reading.

© 2021 the limbic